{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:23:14Z","timestamp":1792664594500,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100023015","name":"ARPA-H","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA202752-01A1"],"award-info":[{"award-number":["R01CA202752-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA249992-01A1"],"award-info":[{"award-number":["R01CA249992-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1U01CA239055-01"],"award-info":[{"award-number":["1U01CA239055-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA268207-01A1"],"award-info":[{"award-number":["R01CA268207-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1U54CA254566\\u201301"],"award-info":[{"award-number":["1U54CA254566\\u201301"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA220581-01A1"],"award-info":[{"award-number":["R01CA220581-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA208236-01A1"],"award-info":[{"award-number":["R01CA208236-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA269181"],"award-info":[{"award-number":["U01CA269181"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1U01CA248226-01"],"award-info":[{"award-number":["1U01CA248226-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA216579-01A1"],"award-info":[{"award-number":["R01CA216579-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA257612-01A1"],"award-info":[{"award-number":["R01CA257612-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32DK108735"],"award-info":[{"award-number":["T32DK108735"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA268287-01A1"],"award-info":[{"award-number":["R01CA268287-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011621","name":"Winship Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.canlet.2025.218059","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T07:07:00Z","timestamp":1758697620000},"page":"218059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["AI-informed computational pathology classifier predicts outcomes across treatment modalities in muscle-invasive urothelial carcinoma"],"prefix":"10.1016","volume":"634","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1598-4287","authenticated-orcid":false,"given":"Kamal","family":"Hammouda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7784-4901","authenticated-orcid":false,"given":"Naoto","family":"Tokuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3002-0937","authenticated-orcid":false,"given":"Germ\u00e1n","family":"Corredor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilak","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Dakarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Genega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Y.","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Paul G.","family":"Pavicic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Marcela","family":"Diaz-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0455-9891","authenticated-orcid":false,"given":"Tuomas","family":"Mirtti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8702-4643","authenticated-orcid":false,"given":"Xavier","family":"Farr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-0399","authenticated-orcid":false,"given":"Anant","family":"Madabhushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.218059_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2025.218059_bib2","first-page":"404","article-title":"Treatment of muscle\u2010invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2025.218059_bib3","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2025.218059_bib4","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218059_bib5","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41585-024-00872-0","article-title":"The evolving treatment landscape of metastatic urothelial cancer","volume":"21","author":"Roviello","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.canlet.2025.218059_bib6","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218059_bib7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are Unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218059_bib8","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218059_bib9","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts general hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2025.218059_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2025.218059_bib11","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bju.16366","article-title":"Trimodal therapy vs radical cystectomy in patients with muscle\u2010invasive bladder cancer: a systematic review and meta\u2010analysis of comparative studies","volume":"134","author":"Ditonno","year":"2024","journal-title":"BJU Int."},{"key":"10.1016\/j.canlet.2025.218059_bib12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2025.218059_bib13","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218059_bib14","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218059_bib15","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.canlet.2025.218059_bib16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1634\/theoncologist.2018-0084","article-title":"FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy","volume":"24","author":"Suzman","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2025.218059_bib17","series-title":"Administration D. Nivolumab for Treatment of Urothelial Carcinoma","year":"2017"},{"key":"10.1016\/j.canlet.2025.218059_bib18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1200\/JCO.2021.39.6_suppl.391","article-title":"First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC)","volume":"39","author":"Bajorin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218059_bib19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3390\/cancers14030636","article-title":"Tumor-infiltrating lymphocytes as biomarkers of treatment response and long-term survival in patients with rectal cancer: a systematic review and meta-analysis","volume":"14","author":"Orhan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2025.218059_bib20","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/s41467-025-56462-0","article-title":"Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts","volume":"16","author":"Boll","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.218059_bib21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41416-022-02119-4","article-title":"Tumour-infiltrating lymphocytes: from prognosis to treatment selection","volume":"128","author":"Brummel","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2025.218059_bib22","series-title":"Bladder Cancer. StatPearls [Internet]","author":"Leslie","year":"2024"},{"key":"10.1016\/j.canlet.2025.218059_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1609871","article-title":"Advances in the immunological microenvironment and immunotherapy of bladder cancer","volume":"16","author":"Meng","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.218059_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41571-024-00984-x","article-title":"Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach","volume":"22","author":"Lopez de Rodas","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218059_bib25","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-18-2013","article-title":"Spatial architecture and arrangement of tumor-infiltrating lymphocytes for predicting likelihood of recurrence in early-stage non\u2013small cell lung cancer","volume":"25","author":"Corredor","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218059_bib26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/jnci\/djab215","article-title":"An imaging biomarker of tumor-infiltrating lymphocytes to risk-stratify patients with HPV-associated oropharyngeal cancer","volume":"114","author":"Corredor","year":"2022","journal-title":"J. Natl. Cancer Inst.: Journal of the National Cancer Institute"},{"key":"10.1016\/j.canlet.2025.218059_bib27","series-title":"HistoQC: an Open-Source Quality Control Tool for Digital Pathology Slides","author":"Janowczyk","year":"2019"},{"key":"10.1016\/j.canlet.2025.218059_bib28","author":"Shen"},{"key":"10.1016\/j.canlet.2025.218059_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2025.218059_bib30","author":"Ronneberger"},{"key":"10.1016\/j.canlet.2025.218059_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.media.2019.101563","article-title":"Hover-Net: simultaneous segmentation and classification of nuclei in multi-tissue histology images","volume":"58","author":"Graham","year":"2019","journal-title":"Med. Image Anal."},{"key":"10.1016\/j.canlet.2025.218059_bib32","article-title":"Computational pathology reveals unique spatial patterns of immune response in H& E images from COVID-19 autopsies: preliminary findings","volume":"8","author":"Toro","year":"2021","journal-title":"J. Med. Imaging"},{"key":"10.1016\/j.canlet.2025.218059_bib33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3","article-title":"The lasso method for variable selection in the cox model","volume":"16","author":"Tibshirani","year":"1997","journal-title":"Stat. Med."},{"key":"10.1016\/j.canlet.2025.218059_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1228907","article-title":"Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy","volume":"14","author":"Johansen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2025.218059_bib35","first-page":"2825","article-title":"VG and GA and MV and TB and GO and BM and PP and WR and DV and others. Scikit-learn: machine learning in Python","author":"Pedregosa","year":"2011","journal-title":"J. Mach. Learn. Res."},{"key":"10.1016\/j.canlet.2025.218059_bib36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1214\/aoms\/1177730491","article-title":"On a test of whether one of two random variables is stochastically larger than the other","volume":"18","author":"Mann","year":"1947","journal-title":"Ann. Math. Stat."},{"key":"10.1016\/j.canlet.2025.218059_bib37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2307\/3001968","article-title":"Individual comparisons by ranking methods","volume":"1","author":"Wilcoxon","year":"1945","journal-title":"Biometrics Bull."},{"key":"10.1016\/j.canlet.2025.218059_bib38","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v036.i11","article-title":"Feature selection with the Boruta package","volume":"36","author":"Kursa","year":"2010","journal-title":"J. Stat. Software"},{"key":"10.1016\/j.canlet.2025.218059_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju435","article-title":"Objective measurement and clinical significance of TILs in non\u2013small cell lung cancer","volume":"107","author":"Schalper","year":"2015","journal-title":"J. Natl. Cancer Inst.: Journal of the National Cancer Institute"},{"key":"10.1016\/j.canlet.2025.218059_bib40","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/lary.28044","article-title":"Tumor\u2010infiltrating lymphocyte quantification stratifies early\u2010stage human papillomavirus oropharynx cancer prognosis","volume":"130","author":"Faraji","year":"2020","journal-title":"Laryngoscope"},{"key":"10.1016\/j.canlet.2025.218059_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research","volume":"15","author":"Koo","year":"2016","journal-title":"J. Chiropr Med."},{"key":"10.1016\/j.canlet.2025.218059_bib42","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2025.218059_bib43","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.21.01003","article-title":"Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218059_bib44","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.21.01485","article-title":"Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial","volume":"40","author":"Funt","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218059_bib45","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.eururo.2023.05.011","article-title":"Checkpoint inhibitors in urothelial carcinoma\u2014future directions and biomarker selection","volume":"84","author":"Meeks","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2025.218059_bib46","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy [Figure presented]","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2025.218059_bib47","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer[Formula presented]","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2025.218059_bib48","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-16-1417","article-title":"Atezolizumab: a PD-L1\u2013blocking antibody for bladder cancer","volume":"23","author":"Inman","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218059_bib49","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.3390\/cancers12113153","article-title":"Clinical impact of tumor-infiltrating lymphocytes and PD-L1-positive cells as prognostic and predictive biomarkers in urological malignancies and retroperitoneal sarcoma","volume":"12","author":"Miyake","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2025.218059_bib50","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.clgc.2024.01.008","article-title":"The prognostic value of tumor infiltrating lymphocytes after radical cystectomy for bladder cancer: a systematic review and meta-analysis","volume":"22","author":"Kawada","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.canlet.2025.218059_bib51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2024.01.023","article-title":"Prognostic impact and spatial interplay of immune cells in urothelial cancer","volume":"86","author":"Debatin","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2025.218059_bib52","article-title":"Regulation of PD-L1: emerging routes for targeting tumor immune evasion","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2025.218059_bib53","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1073\/pnas.0611618104","article-title":"CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma","volume":"104","author":"Sharma","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.canlet.2025.218059_bib54","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1200\/JCO.2024.42.4_suppl.686","article-title":"AI-based morphologic model for prediction of individual patient response to immune checkpoint inhibitors for bladder cancer","volume":"42","author":"Nair","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218059_bib55","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41746-025-01560-y","article-title":"Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning","volume":"8","author":"Bai","year":"2025","journal-title":"npj Digit. Med."},{"key":"10.1016\/j.canlet.2025.218059_bib56","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.218059_bib57","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/s43018-024-00772-7","article-title":"LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features","volume":"5","author":"Chang","year":"2024","journal-title":"Nat. Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525006317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525006317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:18:49Z","timestamp":1785273529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525006317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":57,"alternative-id":["S0304383525006317"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218059","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AI-informed computational pathology classifier predicts outcomes across treatment modalities in muscle-invasive urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218059"}}